ABSTRACT N-Butylidenephthalide (BP), isolated from the chloroform extract of Angelica sinensis, has been examined for its antitumor effects on glioblastoma multiforme brain tumors; however, little is known about its antitumor effects on hepatocellular carcinoma cells. Two hepatocellular carcinoma cell lines, HepG2 and J5, were treated with either N-butylidenephthalide or a vehicle, and cell viability and apoptosis were evaluated. Apoptosis-related mRNA and proteins expressed, including orphan receptor family Nurr1, NOR-1, and Nur77, were evaluated as well as the effect of N-butylidenephthalide in an in vivo xenograft model. N-Butylidenephthalide caused growth inhibition of both the cell lines at 25 g/ml. Furthermore, N-butylidenephthalide-induced apoptosis seems to be related to Nur77 translocation from nucleus to cytosol, which leads to cytochrome c release and caspase-3-dependent apoptosis. N-Butylidenephthalide-related tumor apoptosis was associated with phosphatidylinositol 3-kinase/protein kinase B (AKT)/glycogen synthase kinase-3␤ rather than the mitogen-activated protein kinase or protein kinase C pathway. Blockade of AKT activation enhanced proliferation inhibition and the induction of phosphor-Bcl-2 and Nur77 proteins. Besides, the increasing apoptosis by BP via transfection wild-type cAMP-response element-binding protein (CREB) into tumor cell was suppressed by dominant phosphorylation site mutation of CREB. This finding suggested CREB pathway was also partly involved in tumor apoptosis caused by BP. Administration of N-butylidenephthalide showed similar antitumoral effects in both HepG2 and J5 xenograft tumors. N-Butylidenephthalide induced apoptosis in hepatocellular carcinoma cells, both in vitro and in vivo, suggesting a potential clinical use of this compound for improving the prognosis of hepatocellular carcinoma cells.
rently, conventional chemotherapy for the treatment of advanced tumors, although quite effective, has been associated with adverse events, which is a dose-limited factor. It is clear that new therapeutic options are necessary. Chinese medicine provides novel and efficacious agents for the treatment of a variety of diseases, including those that could not be cured by Western medicine. It was demonstrated that Chinese herbs had antitumoral effects with current chemotherapy in treatment of hepatocellular carcinoma (Yano et al., 1994; Kao et al., 2001) .
Angelica sinensis (Oliv.) Diels (AS), also referred to as dong quai or danggui, a traditional Chinese medicine for menopausal symptoms (Yim et al., 2000; Ye et al., 2001a,b) , has been clinically administrated for several gynecological symptoms in the United States (Abebe, 2002) . In our previous study, the chloroform extract of AS and N-butylidenephthalide (BP), derived from the chloroform extract of AS, both revealed dramatic antitumor effects, causing growth arrest and apoptosis of malignant brain tumors in vitro and in vivo (Tsai et al., 2005 (Tsai et al., , 2006 . To date, little is known about its antitumor effects on HCC cells.
Nur77 [nerve growth factor (NGF)-induced B or TR3] is a unique transcription factor belonging to the orphan nuclear receptor superfamily (Chang et al., 1989) . Unlike other orphan receptors, it is believed that no endogenous ligands are required. In malignant cells such as colon and prostate cancer cells, Nur77 is located in the nucleus and functions as an oncogenic survival factor. Nonetheless, Nur77-caused cell apoptosis via Bcl-2 binding upon administration of certain chemotherapeutic agents induces its migration to mitochondria (Jü rgensmeier et al., 1998; Lin et al., 2004) . A dominant-negative form of Nur77 that lacks the N-terminal transactivation domain blocks T-cell receptor (TCR)-mediated apoptosis, indicating that Nur77 induction plays a crucial role in the TCRmediated death of T cells (Woronicz et al., 1994; Winoto, 1997; Winoto and Littman, 2002) . Furthermore, the diverse biological activities of Nur77 depend on its subcellular localization. It has been known the induction of Nur77 expression and translocation by antitumorigenic compounds involves members of the mitogen-activated protein kinase (MAPK) family (Kovalovsky et al., 2002; Kolluri et al., 2003) . Recent studies have demonstrated that both activation of c-Jun NH 2 -terminal kinases (JNK) and inhibition of AKT play a role in translocation of Nur77 from the nucleus to the cytoplasm (Han et al., 2006) . In addition, extracellular signal-regulated kinase (ERK) activation plays an important role in cadmium-induced Nur77 expression and apoptosis in lung cancer A549 cells (Shin et al., 2004) .
Using oligodeoxynucleotide-based microarray screening, we demonstrated previously that the expression of orphan receptors, including Nurr1, NOR-1, and Nur77, was induced after exposure to BP in brain tumor cells (data not shown). In this study, we characterized the induction of orphan receptor family genes and assessed the possible role of Nur77-induced growth inhibition and apoptosis in vitro and in vivo in HCC cells after treatment with BP. These results distinguish the mode of action of BP from other stimuli and suggest a novel mechanism for understanding the downstream effectors of BP-induced apoptosis in HCC cells.
Materials and Methods
Cell Lines and Cell Culture. The human hepatocellular carcinoma cell line HepG2 (BCRC 60380) was obtained from Bioresources Collection and Research Center (Hsin Chu, Taiwan). The J5 line of human hepatocellular carcinoma cells was kindly provided by Dr. M. J. Chou (Graduate Institute of Basic Medical Science, Chang Gung University, Tao-Yuan, Taiwan, Republic of China). The HepG2 cells were maintained with Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, and the J5 cells were maintained with RPMI 1640 medium containing 10% fetal bovine serum at 37°C in a humidified atmosphere containing 5% CO 2 .
Chemicals and Reagents. BP (mol. wt., 188.23) was purchased from Lancaster Synthesis Ltd. (Newgate Morecambe, UK) and dissolved in dimethyl sulfoxide (DMSO) to a concentration of 100 g/ml and stored at Ϫ20°C as a master stock solution. RPMI 1640 medium, Eagle's minimal essential medium, fetal bovine serum, penicillin, streptomycin, trypsin/EDTA, and NuPAGE Bis-Tris electrophoresis system (precast polyacrylamide mini-gel) were purchased from Invitrogen (Carlsbad, CA). RNA isolation kit was purchased from QIAGEN (Valencia, CA). DMSO, 3-(4,5-dimethyl thizol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), CD437, nuclear export inhibitor leptomycin B (LMB), and horseradish peroxidase-conjugated secondary antibodies were purchased from Sigma-Aldrich (St. Louis, MO). ERK1/2 kinase inhibitor PD98059 and JNK inhibitor SP600125 and phosphor-Bcl-2 (1:500) antibody were purchased from R&D Systems (Minneapolis, MN). Protein kinase C (PKC) inhibitor Gö6983, p38 inhibitor SB203580, and PI3K inhibitor LY294002 were purchased from Calbiochem (San Diego, CA). AKT (1:1000) antibody was purchased from Abcam plc (Cambridge, UK). Nur77 (1:1000), ERK1/2 (1:1000), phosphor-ERK1/2 (1:500). p38 (1:2000), phosphor-p38 (1:1000), JNK (1:1000), phosphor-JNK (1:500), Bcl-2 (1:1000), phosphor-AKT (1:1000), c-Fos, caspase-3 (1:1000), cleaved caspase-3 (1:500), PARP (1:1000), and cleaved PARP (1:500) antibodies were purchased from Cell Signaling Technology Inc. (Danvers, MA). CREB and phosphor-CREB were purchased from Santa Cruz Biotechnology, Inc. Electrophoretic mobility shift assay (EMSA) gel shift kit and nuclear extraction kit were purchased from Panomics Inc. (Redwood, CA). Removal Reagent was from Dainippon Pharmaceutical Co. (Osaka, Japan). Annexin V-FLOUS staining kit was from Roche Molecular Biochemicals (Mannheim, Germany). Polyvinylidene difluoride membranes, bovine serum albumin protein assay kit, and Western blot chemiluminescence reagent were purchased from GE Healthcare (Chalfont St. Giles, Buckinghamshire, UK). Dominant-negative CREB vectors were purchased from BD Biosciences (San Jose, CA).
RT-PCR Analysis. Cells were treated with 50 g/ml BP for the indicated times (0.5, 1, 3, and 6 h). As treatment control, vehicle (DMSO) was used. After treatment, cells were washed with phosphate-buffered saline, pH 7.4, trypsinized, and scraped from the plate. Total RNA from each sample was isolated by using RNeasy Midi kit and RNase-free DNase set (QIAGEN) according to the manufacturer's protocols. RNA was checked by electrophoresis and ethidium bromide staining on a 1.5% agarose gel. One microgram of total RNA from each sample was used to generate cDNA using the Omniscript RT kit (QIAGEN) according to manufacturer's protocol. One microgram of cDNA was amplified in the presence of 1 mol of the following primers: Nur77 (F), 5Ј-CGACCCCCTGACCCCTGA-GTT-3Ј; Nur77 (R), 5Ј-GCCCTCAAGGTGTTGGAGAAGT-3Ј; Nurr1 (F), 5Ј-CGACATTTCTGCCTTCTCC-3Ј; Nurr1 (R), 5Ј-GGTAAAGT-GTCCAGGAAAAG-3Ј; NOR-1 (F), 5Ј-TCTGCCTTCCAAACCAAAG-3Ј; NOR-1 (R), 5Ј-TGATGGAAAGTCTGAGGAC-3Ј; GAPDH (F), 5Ј-TGAAGGTCGGAGTCAACGGATTTGGT-3Ј; and GAPDH (R), 5Ј-CATGTGGGCCATGAGGTCCACCAC-3Ј, with Taq DNA polymerase (Takara Shuzo Co., Shiga, Japan) ( Table 1 ). The thermal cycling profile was composed of an initial denaturation step at 95°C for 10 min, 35 cycles of 30 s of denaturation at 95°C, 30 s of annealing at n-BP-Induced Nur77 Expression and Apoptosis in Liver Cancer 60°C, and 1 min of extension at 72°C, with a final 10-min extension step at 72°C. The intensity of bands was analyzed by GS-800 calibrated imaging densitometer (Quantity One 4.0.3 software; Bio-Rad, Hercules, CA), and levels of GAPDH were used as control.
Cell Fractionation. To investigate whether Nur77 translocates from the nucleus to the cytoplasm., cytoplasmic, nuclear, and mitochondrial fractions were separated by mitochondrial fractionation kit (Active Motif Inc., Carlsbad, CA) according to the manufacturer's instructions. In brief, the J5 cells (5 ϫ 10 6 ) were treated with BP in the indicated times. The cells were harvested and washed once with phosphate-buffered saline (PBS). The cells were resuspended for 15 min in ice-cold cytosolic buffer (Active Motif Inc.). On ice, the cells were homogenized using 30 to 50 strokes with a homogenizer. Cells were then sheared by passing them through a 22-gauge needle. The nuclear fraction was recovered by centrifugation at 800g for 20 min at 4°C. The "low-speed" pellet was lysed with lysis buffer on ice for 30 min. The low-speed supernatant was centrifuged at 10,000g for 20 min at 4°C to obtain the mitochondrial fraction (pellet) and the cytosolic fraction (supernatant). The mitochondrial fraction was further lysed in the mitochondria buffer (Active Motif Inc.) and incubating on ice for 15 min.
Western Blot Analysis. Approximately 5 ϫ 10 6 cells were cultured in 100-mm 2 dishes and then incubated in various concentrations of isochaihulactone for the indicated times. The cells were lysed on ice with 200 l of lysis buffer (50 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 5 mM MgCl 2 , 0.5% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 1 g/ml pepstatin, and 50 g/ml leupeptin) and centrifuged at 13,000g at 4°C for 20 min. The protein concentrations in the supernatants were quantified using a bovine serum albumin protein assay kit. Electrophoresis was performed on a NuPAGE Bis-Tris electrophoresis system using 50 g of reduced protein extract per lane. Resolved proteins were then transferred to polyvinylidene difluoride membranes. Filters were blocked with 5% nonfat milk overnight and 1:500 dilutions of primary antibodies for 1 h at room temperature. Membranes were washed with three times with 0.1% Tween 20 and incubated with 1:5000 dilution of horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. All proteins were detected using Western Lightning Chemiluminescence Reagent Plus kit (PerkinElmer Life and Analytical Sciences, Boston, MA) and quantified using a densitometer.
Growth Inhibition Assay. The viability of the cells after treated with various chemicals was evaluated using MTT assay preformed in triplicate. In brief, the cancer cells (5 ϫ 10 3 ) were incubated in 96-well plates containing 200 l of the culture medium. Cells were permitted to adhere for 12 to 18 h, and then they were washed with PBS. Solutions were always prepared fresh by dissolving 0.2% DMSO or drugs in culture medium and adding the medium to HepG2 and J5 cells. For inhibitor treatment experiments, cells were treated with 50 g/ml BP and preincubated for 1 h with 25 and 50 M ERK1/2 kinase inhibitor PD98059, 10 and 20 M PI3K inhibitor LY294002, or 10 and 20 M PKC inhibitor Gö6983. After 24 h of exposure, the drug-containing medium was removed, cells were washed with PBS, and replaced with fresh medium. The cells in each well were then incubated in culture medium with 500 g/ml MTT for 4 h. After the medium was removed, 200 l of DMSO and 25 l of glycine buffer (0.1 M glycine and 0.1 M NaCl, pH 10.5) were added to each well. Absorbance at 570 nm of the maximum was detected by a PowerWave X microplate enzyme-linked immunosorbent assay reader (BioTek Instruments, Winooski, VT). The absorbance for DMSO-treated cells was considered as 100%. The results were determined by three independent experiments. Detection of Apoptosis. Apoptosis was analyzed according to the method described by van Engeland et al. (1998) to detect the integrity of cellular membrane and the externalization of phosphatidylserine (van Engeland et al., 1998) . In brief, approximately 10 6 cells were grown in 35-mm-diameter plates. The cells were treated with various herbal extracts and chemicals according to the experimental design and then labeled with 10 g/ml Annexin V-FLOUS and 20 g/ml PI before harvesting. After labeling, the cells were washed with binding buffer and harvested by scraping. Cells were resuspended in binding buffer at a concentration of 2 ϫ 10 5 cells/ml before analysis by flow cytometry (FACScan; BD Biosciences). The data were analyzed on WinMDI software (version 2.8; http://facs. scripps.edu/software.html). The percentage of cells undergoing apoptosis was determined by three independent experiments.
Transfection with siRNA. Nur77 small interfering RNA (siRNA) targeting the sequence 5Ј-CAG UCC AGC CAU GCU CCU CUU-3Ј was synthesized (Ambion, Austin, TX). Cells at 50 to 60% confluence were transfected using GeneJammer transfection reagent (Invitrogen) according to the manufacture's protocol (Stratagene, La Jolla, CA) with Nur77 siRNA (with various concentration of 10-50 nM) for 48 h. Medium was removed, and the cells were treated with BP or vehicle for up to 48 h. After incubation, RNA was isolated for RT-PCR, protein isolated for Western blot, and cells were collected for apoptosis analysis.
Construction of Plasmids. Human Nur77 promoter was isolated using a DNA extraction kit according to the manufacturer's protocol (QIAGEN) from volunteer blood. The Ϫ496/ϩ67 (pNur77Ϫ496/ϩ67) Nur77 promoter regions were generated using the following primers: pNur77Ϫ496/ϩ67: sense, 5Ј-CGACGCGTGGCTTGGGAAGGTGTA-AAGGC-3Ј and antisenese, 5Ј-GGAAGATCTCCCAAGTTTCCG-TAGCCAC-3Ј. The amplified product was digested with MluI and BglII restriction enzymes and ligated into pGL3-basic luciferase vector (Promega, Madison, WI) digested with the same enzymes. The AP-1 binding site was mutated using the QuikChange site-mutagenesis kit (Stratagene). For the point mutation of AP-1, sites on the Ϫ496/ϩ67 promoter region were generated using the following primers: pNur77 mut F, 5Ј-CTCCCTGCGTTGATGGAACCCCGCGTGCGTTGCGC-GCGCAGA-3Ј and pNur77 mut R, 5Ј-TCTGCGCGCGCAACGCAC-GCGGGGTTCCATCAACGCAGGGAG-3Ј. Site-specific mutations were confirmed by DNA sequencing. Transfection of the Luciferase Reporter System. HepG2 and J5 cells were plates in six-well plates at 2 ϫ 10 5 cells/well in RPMI 1640 medium supplemented with 10% fetal bovine serum. After growth overnight, plasmid mixtures containing 2 g of Nur77 promoter linked to luciferase and 0.2 g of pRT-null (Promega) were transfected by GeneJammer reagent according to the manufacturer's protocol. After 48-h transfection, the cells were harvested in 1ϫ luciferase lysis buffer, and luciferase activity was determined and normalized to the pRL-null luciferase activity with a dual-luciferase assay kit (Promega). For the BP treatment, the cells were treated with the drug in the absence of serum for 24 h and then assayed for luciferase activity. The results were determined by three independent experiments.
Electrophoretic Mobility Shift Assay. J5 cells were seeded at 10 ϫ 10 6 cells per 100-mm dish and incubated with 50 g/ml BP for 3 h. Nuclear extracts were prepared using the nuclear extraction kit (Panomics Inc.) according to the instructions provided by the manufacturer. The EMSA was performed using a nonradioactive EMSA kit (Panomics Inc.) according to the experimental procedures provided by the manufacturer. In brief, nuclear protein (10 g) was incubated in binding buffer (10 mM Tris, pH 7.5, 1 mM EDTA, 5 mM MgCl 2 , 25 mM NaCl, 5% glycerol, 5% sucrose, and 0.01% Nonidet P-40) for 10 min at 37°C. Poly(dI-dC) (3 g) was added to samples before addition of the oligonucleotide probe. Double-stranded consensus oligonucleotides for the transcription factors AP-1 (5Ј-CGCTT-GATGAGTCAGCCGGAA-3Ј) were end-labeled with [␥- 32 P]ATP using T4 polynucleotide kinase, and 1 ϫ 10 5 counts/min were added to reaction mixtures. For competition studies, 100-fold excess of unlabeled AP-1 oligonucleotide or noncompetitive mutant oligonucleotides 5Ј-AGTTGAGGCGACTTTCCCAGGC-3Ј (nuclear factor-B mutant) and 5Ј-CGCTGATATTGGCGGAA-3Ј (AP-1 mutant) was added before addition of the radiolabeled probe.
Caspase Activity Assay. Activity of caspase-3 and caspase-9 was detected by using a fluorometric assay kit (Promega) according to the manufacturer's protocol. In brief, 2 ϫ 10 6 control or treated cells were lysed in 50 l of cold lysis buffer and incubated in ice for 10 min. Fifty microliters of cell lysates was added to 50 l of reaction buffer and 5 l of fluorogenic report substrates specific for caspase-3 or caspase-9 in a 96-well microplate. After incubation at 37°C for 1 h, the fluorescence from the cleaved C-terminal side of the aspartate residue of DEVD-7-amino-4-trifluoromethyl coumarin was detected by a fluorescence microplate reader (Fluoroskan Ascent; Thermo Fisher Scientific, Waltham, MA), with excitation at 400 nm and emission at 505 nm.
CREB Plasmid Transient Transfection. J5 cells were plated in six-well plates at 2 ϫ 10 5 cells/well in RPMI 1640 medium supplemented with 10% fetal bovine serum. After growth overnight, one of the pCMV (CMV; empty vector), pCMV-CREB (wild type), pCMV-KCREB (K), and pCMV-CREB133 (C133) were transfected by GeneJammer reagent according to the manufacturer's protocol. After 48-h transfection, the cells were treated with 50 g/ml BP for 1 or 3 h. After 1 h, the cell were harvested and assayed by RT-PCR (for Nur77 RNA expression) and Western blotting (for c-Fos protein expression).
The cells were treated with 50 g/ml BP for 3 h, and then they were harvested and assayed Nur77 protein expression.
Antitumor Activity in Vivo. Xenograft mice were used as a model system to study the cytotoxicity effect of BP in vivo. The implantation of cancer cells was carried out similarly to that described in previous reports. Female congenital athymic BALB/c nude (nu/nu) mice were purchased from National Sciences Council (Taipei, Taiwan), and all procedures were performed in compliance with the standard operating procedures of the Laboratory Animal Center of Tzu Chi University (Hualien, Taiwan). All experiments were carried out using 6-to 8-week-old mice weighing 18 to 22 g. The animals were s.c. implanted with 2 ϫ 10 6 HepG2 or 5 ϫ 10 6 J5 cells into their backs. When the tumor reached 80 to 120 mm 3 in volume, animals were divided randomly into control and test groups consisting of six mice per group (day 0). Daily s.c. administration of BP, dissolved in a vehicle consisting of 20% Tween 80 in normal saline (v/v), was performed from days 0 to 4 far from the inoculated tumor sites (Ͼ1.5 cm). The control group was treated with vehicle only. The mice were weighed three times a week up to days 21 to 28 to monitor the effects and the same time the tumor volume was determined by measurement of the length and width of the tumor. The tumor volume at day n (TVn) was calculated as TV (cubic millimeters) ϭ (length ϫ width 2 )/2. The relative tumor volume at day n (RTVn) versus day 0 was expressed according to the following formula: RTVn ϭ TVn/TV0. Tumor regression [T/C (%)] in treated versus control mice was calculated using T/C (%) ϭ (mean RTV of treated group)/(mean RTV of control group) ϫ 100. Xenograft tumors as well as other vital organs of treated and control mice were harvested and fixed in 4% formalin, embedded in paraffin, and cut into 4-mm sections for histologic study.
Immunocytochemistry Staining. J5 cells (1 ϫ 10 3 ) were treated with 50 g/ml BP in the presence or absence of the nuclear export inhibitor LMB at 60 nM. For 3-, 6-, and 12-h incubation, cells were fixation with cold 3.7% formaldehyde. The fixed cells were washed twice in PBS and incubated in cold permeabilization solution (0.1% Triton X-100 and 0.1% sodium citrate). After inactivating endogenous peroxidase with 3% H 2 O 2 , the cells were washed with PBS again and incubated with an anti-Nur77 antibody at room temperature, followed by an overnight incubation with a 100-fold dilution of anti-Nur77 rabbit polyclonal antibody (Cell Signaling Technology Inc.) in blocking solution. Subsequently, the immune complexes were visualized using the horseradish peroxidase-conjugated anti-goat IgG secondary antibodies (1/1000 dilution; Santa Cruz Biotechnology, Inc.) and LSAB2 system (Dako North America, Inc., Carpinteria, CA), respectively, and then incubated for 10 min with 0.5 mg/ml diaminobenzidine and 0.03% (v/v) H 2 O 2 in PBS. Finally, sections were counterstained with hematoxylin, mounted, observed under a light microscope at 400ϫ magnification, and photographed.
Immunohistochemical Staining. All tumor tissues (s.c. HepG2 and J5 tumors with or without BP treatment) were fixed in 4% Formalin at 4°C for 16 h and then embedded in paraffin. Paraffin sections (5 m) were deparaffinized in xylene and rehydrated through a graded series of ethanol solutions. The sections were incubated with blocking solutions (5% milk power, 1% bovine serum albumin in phosphate-buffered saline) for 60 min at room temperature, followed by an overnight incubation with a 100-fold dilution of anti-Nur77 rabbit polyclonal antibody (Cell Signaling Technology Inc.) in blocking solution. Subsequently, the immune complexes were visualized using the horseradish peroxidase-conjugated anti-goat IgG secondary antibodies (1/1000 dilution; Santa Cruz Biotechnology, Inc.) and LSAB2 system (Dako North America, Inc.), respectively, and then incubated for 10 min with 0.5 mg/ml diaminobenzidine and 0.03% (v/v) H 2 O 2 in PBS. Finally, sections were counterstained with hematoxylin, mounted, observed under a light microscope at 400ϫ magnification, and photographed.
Statistical Analysis. The data are shown as mean with standard deviation. The statistical difference was analyzed using the Stu- 
Results

BP-Related Growth Inhibition and Apoptosis of HCC Cells in Vitro.
In our previous studies (Tsai et al., 2005 (Tsai et al., , 2006 , we demonstrated the antitumoral effects of BP on glioblastoma multiforme (GBM) brain tumors both in vitro and in vivo. In this study, we selected HepG2 and J5 HCC for further investigations because of its poor prognosis and because it requires a new strategy in clinical practice. MTT assay revealed that BP had a strong antiproliferative effect on HepG2 and J5 cells (Fig. 1A) . The IC 50 value of HepG2 and J5 cells was 25 g/ml after 48 h of treatment. Compared with untreated cells, BP-treated HepG2 and J5 cells showed obvious cell shrinkage and chromosomal fragmentation typical of cells undergoing apoptosis (data not shown). To elucidate the BP mode of action, the effect of BP on apoptosis was examined. Flow cytometry analysis showed that BP treatment induced apoptosis in a time-and concentration-dependent manner (Fig. 1B) .
BP-Induced mRNA and Protein Expression of Nurr1, NOR-1, and Nur77 in HepG2 and J5 Cells and Nur77 Migration from Nucleus to Cytoplasm. To elucidate the mechanism by which BP induces growth inhibition and apoptosis in GBM cells, we used an oligodeoxynucleotidebased microarray screening assay to identify BP-mediated gene expression. Orphan receptor expression, including Nurr1, NOR-1, and Nurr77, was highly induced (data not shown). In this study, the expression of orphan receptors in BP-treated HepG2 and J5 cells was examined, with a focus on the role of BP-induced Nur77 expression. After treatment with BP, mRNA expression of Nurr1, NOR-1, and Nurr77 in both HCC cell lines examined in this study was enhanced in a time-dependent manner, as illustrated in Fig. 2A . Furthermore, the protein expression of Nurr1, NOR-1, and Nur77 was all enhanced in a time-dependent manner. Nurr77 was significantly induced after 3 h of treatment and was maximally expressed 12 h after treatment with BP (Fig. 2B) . Because Nur77 migrates from the nucleus to mitochondria to induce apoptosis in response to certain apoptotic stimuli (Yano et al., 1994; Ye et al., 2001a,b) , the subcellular localization of Nur77 in J5 was examined. Immunoblotting revealed that Nur77 predominantly localized in the nucleus in the absence of BP treatment. When cells were treated with BP, however, enhanced Nur77 expression in the cytoplasm of J5 cells was noted (Fig. 2C) . To further elucidate whether BP-induced translocation of Nur77 was associated with the following apoptosis in J5 cells, LMB, which can specifically inhibit protein exportation from the nucleus (Yoshida et al., 1990; Fornerod et al., 1997) was used. Translocation of Nur77 could be completely blocked by LMB, with Nur77 remaining in the nucleus after 12-h treatment with BP (Fig. 2, D and F) . Furthermore, it was also reveled that apoptotic index was only 6.2%, indicating that BP-induced apoptosis was concurrently blocked (Fig. 2F) .
BP-Induced J5 cells Apoptosis by Nur77-Mediated Expression. The suppression of Nur77 by Nur77 siRNA was evident in a concentration-dependent manner, as determined by RT-PCR (Fig. 3A) and Western blot analysis (Fig. 3B) . To further determine the role of Nurr77 in BP-induced apoptosis, flow cytometry analysis was performed to identify the percentage of apoptotic cells after treatment with the siRNA of Nur77. Figure 3C shows that between 70 and 90% of apoptosis was inhibited after treating J5 cells with 50 nM Nur77 siRNA with BP. To determine whether MAPKs, PKC, or PI3K/AKT/GSK3 play a role in BP-induced growth inhibition of J5 cells, these cells were treated with BP in the presence or absence of the mitogen-activated protein kinase kinase 1/2 inhibitor PD98059, the p38 inhibitor SB203580, JNK1/2 inhibitor SP600125, PKC inhibitor Gö6983, or the PI3K/AKT/GS3K inhibitor LY294002 (10-50 M). It was shown that PI3K/ AKT/GS3K inhibitor LY294002 enhanced BP-induced growth inhibition in a concentration-dependent manner. In contrast, none of the PKC or MAPK inhibitors could abrogate BPinduced growth inhibition in J5 cells (Fig. 3D) . To determine which PI3K/AKT/GSK3␤ pathways were involved in BP-induced growth inhibition, the effect of BP on AKT inhibition was assessed. Inhibition of phosphor-AKT protein expression after exposure of J5 cells to BP. MAPK and PKC protein expression had no obvious changes after drug treatment (Fig.  3E) . To investigate a possible role for PI3K/AKT/GSK3␤ in the regulation of Nur77, J5 cells were treated with BP in the presence or absence of the PI3K inhibitor LY294002. Using Western blot analysis, an inhibition of PI3K and AKT expression with LY294002 enhanced phosphor-Bcl-2 and Nu77 protein levels after treatment with BP was noted (Fig. 3F) , suggesting that activation of the PI3K/AKT/GSK3␤ signaling A, mRNA expression of Nurr1, NOR-1, and Nurr77 in the cells treated with 50 g/ml BP for various durations (0.5, 1, 3, and 6 h) as indicated. Cells were collected and total RNA isolated for RT-PCR analysis, and expression of GAPDH was used as an internal control. B, protein expressions of Nurr77 in the cells treated with 50 g/ml BP or vehicle for various durations (3, 6, 12, 24, and 48 h) as indicated. These expressions were assessed by Western blot assay, and expression of ␤-actin was used as an internal control. STD indicates cell lysate from CD437-treated cells. C, cells treated with 50 g/ml BP for various duration times (0, 3, 6, 12, and 24 h) as indicated. Nuclear extraction kit (Millipore Bioscience Research Reagents, Temecula, CA) was used for isolation cytoplasm and nucleus. Nur77 expression in both two fractions was evaluated by Western blot analysis, and expression of ␤-actin was used as an internal control. D, J5 cells (5 ϫ 10 3 ) were pretreated with nuclear export inhibitor LMB at 60 nM for 1 h, followed by 50 g/ml BP for various durations (0, 3, 6, 12, and 24 h) as indicated. Nuclear extraction kit was used for isolation cytoplasm and nucleus. Nur77 expression in both fractions was evaluated by Western blot analysis, and expression of ␤-actin was used as an internal control. E, J5 cells (1 ϫ 10 3 ) were treated with 50 g/ml BP in the presence or absence of the nuclear export inhibitor LMB at 60 nM. For 3-, 6-, and 12-h incubation, the effect of BP on the Nur77 translocation was determined by immunocytochemistry. The Nur77-positive cells were stained brown (400ϫ magnification). F, J5 cells (5 ϫ 10 3 ) were pretreated with nuclear export inhibitor LMB at 60 nM for 1 h, followed by 50 g/ml BP for various durations (0, 3, 6, 12, and 24 h) as indicated. Cells were collected, and apoptosis was analyzed using PI/Annexin V staining. The data represent the mean and SD from three independent experiments.
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BP-Induced Nur77 Expression. To evaluate the importance of the AP1 site of the Nur77 promoter regulating BPinduced Nur77 expression, the pNur77 (Ϫ496)/pGL3 deletion Nur77 promoter construct was generated as shown in Fig. 4A ). These constructs were transfected into J5 cells and treated with vehicle or BP for 6 h. As an internal control, the plasmid pRL-TK (Promega) was used for adjusting transfection efficiency. As illustrated in Fig. 4B , BP treatment resulted in a 30-and 52.5-fold induction of luciferase activity in pNur77 (Ϫ496)/ pGL3 of HepG2 and J5 cells, respectively. As a control, a pGL3 basic promoterless vector was transfected, and no increase in luciferase activity was noted after BP treatment (Fig. 4B) . By pretreating with 20 M LY294002 for 1 h and then adding 50 g/ml BP for an additional 24 h, we found that luciferase activity was increased compared with BP treatment alone in HepG2 cells, whereas there was no obvious change in activity in the presence of the PKC inhibitor Gö6983 (Fig. 4C) .
Furthermore, by EMSA it is noteworthy that the nuclear extracts from the stimulated cells gave a much stronger band than unstimulated cell extracts after treatment drugs for 3 h. We have proved the AP-1 protein is binding in Nur77 promoter in the presence of BP and PI3K inhibitor LY294002. Competition studies with excess unlabeled oligonucleotide, further demonstrated the specificity of the interaction (Fig.  4D) . In addition, c-Fos protein expression was increased in the presence of BP combined LY294002, whereas c-Jun protein expression was not obliviously changed after drug treatment (Fig. 4E ). A, J5 cells were transfected with Nur77 siRNA (siNur77) with various concentrations (10 -50 nM) as indicated for 48 h using GeneJammer transfection reagent. RT-PCR was performed for Nur77. Expression of GAPDH was used as an internal control. B, J5 cells were transfected with siNur77, and Western blot analysis was performed for Nur77. Expression of ␤-actin was used as an internal control. C, siNur77 for various concentrations (10 -50 M) for 48 h using GeneJammer transfection reagent followed by treatment with 50 g/ml BP or vehicle for 48 h. N, cells transfected with 50 M Silencer Negative Control siRNA (Ambion). P, cells treated with 10 nM CD437 for 24 h. Cells were collected, and apoptosis was analyzed using PI/Annexin V staining. The data represent the means Ϯ S.D. of three different experiments. ‫,ء‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01; ‫,ءءء‬ P Ͻ 0.001 versus vehicle. D, J5 cells (5 ϫ 10 3 ) were treated with 50 g/ml BP in the presence or absence of the mitogen-activated protein kinase kinase 1/2 inhibitor PD98059 (25 and 50 M), p38 inhibitor SB203580 (10 and 20 M), JNK1/2 inhibitor SP600125 (10 and 20 M), PKC inhibitor Gö6983 (10 and 20 M), or PI3K inhibitor LY294002 (10 and 20 M). For 24-h incubation, growth inhibition effect was determined by MTT assay. E, J5 cells were treated with BP for various durations (0 -120 min) as indicated. Western blot analysis was performed for ERK, phosphor-ERK, p38, phosphor-p38, JNK1/2, phosphor-JNK1/2, PKC, phosphor-PKC, AKT, and phosphor-AKT antibodies. The expression of ␤-actin was used as an internal control. F, enhancement of phosphor-Bcl-2 expression by PI3K/AKT/GSK3␤ inhibitor in the BP-induced growth inhibition. J5 cells were in incubated in the presence or absence of the PI3K/AKT/GSK3␤ inhibitor LY294002 for 1 h and then treated with BP for 12 h. Western blot analysis was performed for Nur77, Bcl-2, and phosphor-Bcl-2, and expression of ␤-actin was used as an internal control.
BP-Activated Endogenous cAMP-Responsive Gene and BP-Induced Cytotoxicity Was
Enhanced by CREBDependent Transcriptional Activation. First, to establish the assay system for the transcriptional activation of endogenous cAMP-responsive genes, c-Fos response in the presence of 50 g/ml BP was investigated. J5 cells were incubated in the presence of 50 g/ml BP, and expression levels of phosphorylated CREB and c-Fos were analyzed by Western blotting (Fig. 5A) . After various times of exposure of J5 cells to BP, both CREB and c-Fos phosphorylations were up-regulated in a time-dependent manner. CREB phosphorylation was induced at 30 min, whereas activation of c-Fos occurred later, beginning at 60 min. Thus, phosphorylated CREB expression was slightly preceded c-Fos by expression. There were no changes in the total amount of CREB in these experiments (Fig. 5A ). To confirm that the effect of BP is mediated via the CREB-dependent transcriptional activation, we examined whether the coexpression of expanded BP and dominant-negative CREB blocks the suppressive effect of these compounds. We first confirmed that the transcriptional activation of c-Fos and Nur77 were strongly suppressed in J5 cells expressing dominant-negative CREB vectors (pCMV-CREB133 or pCMV-KCREB) cultured in the presence of 50 g/ml BP (Fig. 5, B and C) . In J5 cells expressing the mutated form of CREB, the BP-induced cytotoxicity was significantly abrogated (P Ͻ 0.001), confirming CREB The constructs of Nur77 promoter vectors with point mutations has been described under Materials and Methods. B, Wild-type pNAGϪ496/ϩ67 or TCR mutant vector (pNur77Ϫ496mut12) and pRL-TK cotransfected into HepG2 and J5 cells. These indicated promoter region were fused to luciferase report gene. Each construct (2 g) was cotransfected with 0.2 g of pRL-TK vector into HepG2 and J5 cells using GeneJammer transfection reagent followed by treatment with 50 g/ml BP for 24 h. Cells were lysed, and luciferase activity was measured. Transfection efficiency for luciferase activity was normalized to Renilla reniformis luciferase (pRL-TK vector). The x-axis shows relative luciferase units [firefly luciferase/R. reniformis luciferase (RLU)]. The results show means Ϯ S.D. of three separate transfections. ‫,ء‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01; ‫,ءءء‬ P Ͻ 0.001 versus vehicle. C, HepG2 cells were transfected with pNAGϪ496/ϩ67 reporter plasmid and pRL-TK plasmid. Forty-eight hours after transfection, cells were pretreated with LY294002 for 1 h and then treated with BP for another 24 h. Transfection efficiency for luciferase activity was normalized to R. reniformis luciferase (pRL-TK vector). The x-axis shows relative luciferase units (RLU). The results show means Ϯ S.D. of three separate transfection. D, EMSA analysis of LY294002 and BP stimulation of AP-1 complex formation. Ten micrograms of nuclear protein extracted from untreated (control), LY294002 (LY294002), BP-treated (BP), and LY204002 combined BP-treated J5 cells was incubated with an AP-1, double-stranded oligonucleotide as described under Materials and Methods (In combined treatment experiments, J5 cells were in incubated in the presence of the PI3K/AKT/GSK3␤ inhibitor LY294002 for 1 h and then treated with BP for 12 h.) Binding reactions carried out with the addition of excess (100-fold) unlabeled probe resulted in complete elimination of binding complexes in both control and treated conditions. E, enhancement of c-Fos expression by PI3K/AKT/GSK3␤ inhibitor in the BP-induced growth inhibition. J5 cells were in incubated in the presence or absence of the PI3K/AKT/GSK3␤ inhibitor LY294002 for 1 h and then treated with BP for 3 h. Western blot analysis was performed for c-Fos, c-Jun, and expression of ␤-actin was used as an internal control.
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involvement in the suppression of expanded BP-induced cytotoxicity (Fig. 5D) . BP-Induced Mitiochondria-Dependent Apoptosis in J5 Cells. To examine whether Nur77 results in cytochrome c release after treatment with BP in J5 cells, mitochondria enriched by cytosol/mitochondria fractionation kit was used. In this study, it was noted that cytochrome c migrated from the mitochondria to the cytoplasm after drug treatment in a time-dependent manner (Fig. 6A) . As shown in Fig. 6B , caspase-9 and caspase-3 were both activated in a time-dependent manner using specific fluorogenic peptide substrates after addition of 50 g/ml BP to J5 cells. Because activation of the caspases and cleavage of PARP are crucial mechanisms for induction of apoptosis and initiator caspases (e.g., caspase-1, -2, -8, -9, and -10) are involved in the early stages of the proteolytic cascade, their involvement in BP-induced apoptosis was investigated in J5 cells. It was evidenced that BP-induced apoptosis is associated with activation of caspase-3 and PARP in a time-dependent manner (Fig. 6C) . Otherwise, these results indicated that BP might be related to mitochondria-dependent apoptosis pathway in J5 cells.
BP-Induced in Vivo Growth Inhibition of HepG2 and J5 Xenografts in Nude Mice. To evaluate the antitumor activity of BP in vivo, human liver cancer xenografts were established by s.c. injection of approximately 2 ϫ 10 6 HepG2 and 5 ϫ 10 6 J5 into the dorsal subcutaneous tissue and cells on the backs of nude mice. After the tumor reached approximately 100 to 250 mm 3 , mice were randomized into vehicle control and treatment groups (six animals each) and given a daily s.c. injection of either 0 (control group) or 50, 100, 300, and 500 mg/kg BP (treatment groups) for five successive days. Significant suppression of tumor growth was observed in the BP-50, BP-100, BP-300, and BP-500-treated groups compared with the control group. Besides, overexpression of Nur77 protein in the developing tumor was confirmed by Western blot analysis with BP-treated tumor cells (Fig. 7, A  and B ). There were no significant differences between the control and BP-treated groups with respect to the body weight of the animals (data not shown). Nur77 and caspase-3 expression were up-regulated in the human HepG2 and J5 tumor tissues treated with BP relative to the control group at day 10 after treatment (Fig. 7C) .
Discussion
In our previous study, we examined BP-induced changes in gene expression within GBM brain tumor cells using an oligodeoxynucleotide-based microarray assay. In this study, Nur77 was the gene of interest because it is involved in the apoptotic processes of a variety of cells and tissues, as well as being an immediate-early-response gene induced by growth factors and mitogens (Nakai et al., 1990; Youn et al., 2000) . Nur77 is also rapidly induced by TCR signaling in immature thymocytes and T-cell hybridomas, as well as tumor cells of the lung, prostate, ovary, colon, and stomach (Liu et al., 1994;  BP ( , and pCMV-CREB133 (C133) and incubated in the presence of 50 g/ml BP for 1 h. Western blot analysis was performed for c-Fos antibody. C, J5 cells were transfected with one of the pCMV (CMV; empty vector), pCMV-KCREB (K), and pCMV-CREB133 (C133) and incubated in the presence of 50 g/ml BP. Top, J5 cells were treated with BP for 1 h, and RT-PCR was used to evaluate Nur77 mRNA expression. Bottom, J5 cells were treated with BP for 3 h, and Western blot was used to estimate for the Nur77 protein expression. D, J5 cells were transfected with one of the pCMV (CMV; empty vector), pCMV-CREB (wild type), pCMV-KCREB (K), and pCMV-CREB133 (C133). These cells were treated with 50 g/ml BP for 48 h. Cells were collected, and apoptosis was analyzed using PI/Annexin V staining. The data represent the mean and SD from three independent experiments. ‫,ء‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01; ‫,ءءء‬ P Ͻ 0.001 versus vehicle. Uemura et al., 1998; Stocco et al., 2002; Wilson et al., 2003; Wu et al., 2003; Shin et al., 2004) . To investigate whether BP-induced overexpression of Nur77 is involved in HCC cell apoptosis, Nur77 mRNA and protein induction after BP treatment was evaluated in both HepG2 and J5 cell lines. Nur77 protein translocation from the nucleus to cytoplasm was also studied. In both HepG2 and J5 cells, BP-induced Nur77 protein expression was increased 3 h after BP treatment, with expression being highest after 12 h. Nur77 protein translocation was observed after 6 h of BP treatment. In addition, after the activation of caspase 9 and caspase 3, cytochrome c was detected in the J5 cytoplasm after BP treatment. In cancer cells, it is known that Nur77 functions in the nucleus as an oncogenic survival factor. In response to apoptotic stimuli, Nur77 translocates from the nucleus to the cytoplasm, where it binds to Bcl-2, triggering cytochrome c release and apoptosis . Because inhibition of Nur77 expression and blockade of Nur77 translocation into cytoplasm with siRNA abrogated BP-induced apoptosis, it is possible that Nur77 has a role in BP-induced apoptotic cell death. Moreover, an antitumor effect of BP in a nude mouse xenograft animal model has been reported in which expression of Nur77 is associated with the antitumor activity of BP. Together, these results suggest that the antitumor activity of BP is mediated via Nur77 and that Nur77 might play a role of BP on antitumor effect in HCC cells.
The induction of Nur77 expression has been reported in other cell types as well. Nur77 expression was rapidly induced by nerve growth factor in PC 12 cells via Ca 2ϩ (Milbrandt, 1988; Katagiri et al., 1997) , by cadmium in human lung cell lines via extracellular signal-regulated kinase and protein kinase A (Shin et al., 2004) , and by PGF2a and Butaprost in human embryonic kidney 293/EBMA via protein kinase C (Liang et al., 2004) . In addition, a recent report implicates both activation of JNK and inhibition of AKT in the translocation of Nur77 from the nucleus to the cytoplasm in other cancer models (Han et al., 2006) . Thus, regulation of Nur77 expression may involve diverse intracellular mechanisms that are dependent upon different stimuli. It has been demonstrated that the PI3K inhibitors wortmannin and LY294002 stimulate stress-activated protein kinase/JNK and p38 phosphorylation, in a manner that parallels the inhibition of protein kinase B (AKT) phosphorylation. Fur- (0, 3, 6, 12, 24 , and 48 h) as indicated. Mitochondria enriched using cytosol/mitochondria fractionation kit (Calbiochem). Cytochrome c expression in both fractions was evaluated by Western blot analysis, and expression of ␤-actin was used as an internal control. STD indicates cell lysate from CD437-treated cells. B, J5 cells were treated with 50 g/ml BP for various durations (6, 12, 24, and 48 h) as indicated. The y-axis shows relative caspase-9 and caspse-3 activity. The data represent the means Ϯ S.D. of three different experiments. ‫,ء‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01; ‫,ءءء‬ P Ͻ 0.001 versus vehicle. C, J5 cells were treated with BP for various durations (6, 12, and 24 h) as indicated. Western blot analysis was performed for caspase-3, cleaved caspase-3, PARP, and cleaved PARP. The expression of ␤-actin was used as an internal control.
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at ASPET Journals on April 28, 2017 molpharm.aspetjournals.org thermore, it has been shown by EMSA and supershift analysis that wortmannin stimulates AP-1 complex formation (Sidhu et al., 2001 ). In addition, it has been reported that intrathecal pretreatment with wortmannin and LY294002 produced a dose-dependent increase in naloxone-precipitated jumping, which was accompanied by an increase in expression of spinal Fos protein in both acute and chronic morphine-dependent mice (Yang et al., 2006) .
In this study, we found that BP inhibits AKT protein phosphorylation (Fig. 3E) and that BP has a synergistically cytotoxic effect with LY294002 (Fig. 3D) .
There are some potential cis-acting elements in the Nur77 promoter region. A region from Ϫ496 to Ϫ334 was identified that contains enhancers that are responsive to prostaglandin F 2␣ and Butaprost through the PKC pathway (Liang et al., 2004) . The major PKC signal response element in the Nur77 promoter is an AP-1-like element (Kim et al., 2005) , whereas a Nur77 promoter (Ϫ496 to ϩ67) containing four AP-1 motifs has also been reported (Uemura et al., 1995) . To consider whether the AP-1 motif is involved in the PI3K/AKT/GSK3␤ signaling pathway, as well as further studying the transcription mechanisms of BP-mediated Nur77 mRNA expression, a Nur77 promoter (Ϫ496 to ϩ67) containing these four AP-1 motifs was subcloned into a luciferase reporter plasmid. We found that BP-induced a 30-and 50.2-fold increase in the luciferase activity of HepG2 and J5 cells, respectively, compared with the vehicle control. To investigate whether these AP-1 motifs are functional BP motifs, the protocol of Kim et al. (2005) was used to mutate two AP-1 motifs (Ϫ197 to Ϫ192; Ϫ179 to Ϫ173) within the Nur77 promoter. Mutation of the AP-1 motif resulted in a dramatic decrease of BP-induced Nur77 promoter activity. By pretreating with 20 M LY294002 for 1 h and then adding 50 g/ml BP for an additional 24 h, we found that luciferase activity was increased compared with BP treatment alone in HepG2 cells, whereas there was no obvious change in activity in the presence of the PKC inhibitor Gö6983 (Fig. 4C) .
As indicated by EMSA, nuclear extracts from stimulated cells gave a much stronger binding than unstimulated cell extracts after treatment for 3 h. Here, we demonstrated that AP-1 protein will bind to the Nur77 promoter in the presence of either BP or LY294002. Competition studies with excess unlabeled oligonucleotide further demonstrated the specificity of the interaction. In addition, c-Fos protein expression was increased in the presence of BP combined with LY294002, whereas c-Jun protein expression was not significantly changed after drug treatment. These results suggest that AP-1 may be involved in BP and LY294002-induced Nur77 protein expression. As shown by EMSA, there is a supershift complex formation after BP and LY294002 treatment. At present, we suggest that c-Fos up-regulation might result from this supershift complex formation. These results demonstrate that Nur77 activation is probably enhanced by exposure of HCC cells to LY294002. It is known that CREB is phosphorylated by several stimuli, including Ca 2ϩ and cAMP, and then leads to c-Fos activation (Taurin et al., 2002; Wiggin et al., 2002; Barlow et al., 2006; Lee et al., 2007) . To examine whether the c-Fos induction of BP was due to CREB activation, Western blotting for CREB phosphorylation and dominant-negative CREB transfection analysis were used. After various exposure times of J5 cells to BP, both CREB and c-Fos phosphorylation were up-regulated in a timedependent manner. CREB phosphorylation was induced at 30 min, whereas c-Fos phosphorylation occurred later, beginning at 60 min (Fig. 5A) . We then confirmed that the transcriptional activation of c-Fos and Nur77 was obviously inhibited in J5 cells expressing dominant-negative CREB vectors (Fig. 5, B and C) . Furthermore, we transfected J5 cells with one of the dominant-negative CREB vectors, and we found that the expression of dominantnegative CREB blocks the apoptosis effect of BP in the presence of BP 24 h (Fig. 5D) . It was been demonstrated that nerve growth factor and agents that trigger an increase in intracellular levels of cAMP or Ca 2ϩ induce the phosphorylation of CREB Ser-133 to a similar extent, these stimuli influence the transcription of genes containing cAMP response elements in distinct ways. It is noteworthy that dominant-negative CREB has been shown to completely inhibit the cAMP-induced c-fos gene (Ahn et al., 1998) . As mentioned, Nur77 expression was rapidly induced by NGF in PC-12 cells via Ca 2ϩ (Milbrandt, 1988; Katagiri et al., 1997) . Therefore, a novel finding in this study was not only c-Fos but also CREB phosphorylation in response to BP-induced Nur77 expression. Although the mechanism of activation of CREB phosphorylation needs further study, the observation that CREB phosphorylation precedes c-Fos expression after treatment with BP is probably attributable to the BP-induced growth inhibition.
Until now, the synergistically cytotoxic effect caused by BP and LY294002 is perhaps directly associated with Nur77 protein overexpression and translocation to cytoplasm in HCC cells. This phenomenon should lead to greater inhibition of Bcl-2 and thereby enhanced apoptosis. The critical role of subsequent Nur77 redistribution reveals a novel crosstalk between orphan receptors and their behavior in promoting apoptosis in J5 cells through PI3K/AKT/GSK3␤ signal transduction. Together, these results indicate that AP-1 motif is crucial for BP-induced Nur77 mRNA expression. This phenomenon showed that PI3K inhibition might be related to Nur77 activation and lead to apoptosis.
In summary, the mechanisms underlying the antitumor activity of BP were studied. Our previous studies showed growth inhibition and antitumor activity in a variety of tumor cell lines in vitro and inhibition of xenografts, including GBM brain tumor cells, in vivo (Tsai et al., 2005 (Tsai et al., , 2006 . In this study, it was shown that when HCC cells are exposed to BP, Nur77 is the gene that increases expression the most and the PI3K/AKT/GSK3␤ signaling pathways have been implicated in the regulation of BP-induced apoptosis. These results suggest a gene target for BP, which may be useful for future clinical applications.
